ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses
In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therap...
31 Maalis 202513min
Best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer
This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer. Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing met...
21 Maalis 202526min
Intermediate HCC – The evolving role of IO
Intermediate HCC – The evolving role of IO In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion ...
20 Tammi 202527min
Intermediate HCC – treatment options and strategies
In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr Emil Cohen to explore t...
7 Tammi 202520min
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch
Join the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast series, this episode dive...
3 Joulu 202426min
Testing to treatment of BRAF-mutant metastatic NSCLC
Testing to treatment of BRAF-mutant metastatic NSCLC In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metast...
25 Marras 202423min
HCC podcast series part 1: The use of IO in unresectable HCC
In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep di...
21 Marras 202423min
BRAF-mutated CRC: testing to treatment
Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments for these patients. ...
8 Marras 202425min
